Today: 7 February 2026
Subscribe
Browse Category

NYSE:ELV News 3 December 2025 - 31 December 2025

Artisan Value Fund reveals why it dumped Cigna for Elevance — and why ASML stays a top bet

Artisan Value Fund reveals why it dumped Cigna for Elevance — and why ASML stays a top bet

NEW YORK, December 31, 2025, 12:59 ET Artisan Partners’ Artisan Value Fund said in its third-quarter 2025 investor letter that it sold The Cigna Group and bought Elevance Health, citing rising policy risk around pharmacy benefit managers. The fund also reiterated conviction in ASML Holding, keeping the chip-equipment maker among its top positions. Insider Monkey The portfolio shifts land as investors look for signs that the market’s leadership can broaden beyond AI-linked winners. They also underscore how quickly regulatory scrutiny can reshape the outlook for big healthcare intermediaries. Cigna’s pharmacy benefit manager, or PBM, business sits near the center of
31 December 2025
····
UnitedHealth stock today: UNH rises after hours as traders look ahead to January guidance

UnitedHealth stock today: UNH rises after hours as traders look ahead to January guidance

NEW YORK, December 30, 2025, 5:05 PM ET — After-hours UnitedHealth Group shares were up about 1% at $332.16 in after-hours trading on Tuesday, following the 4 p.m. close. The stock ranged from $329.18 to $336.03 during the day’s session, with about 4.4 million shares traded. The gain came as U.S. stocks ended slightly lower in holiday-thin trading. The S&P 500 slipped 0.14%, the Dow fell 0.20% and the Nasdaq lost 0.23%. Reuters Investors are repositioning as 2025 winds down, and swings can look sharper when volumes are light. “It’s just a healthy rebalancing of allocations more so than an
30 December 2025
····
Elevance Health Stock (NYSE: ELV) News Today: Credit Ratings, ACA Subsidy Vote, and Analyst Forecasts on Dec. 12, 2025

Elevance Health Stock (NYSE: ELV) News Today: Credit Ratings, ACA Subsidy Vote, and Analyst Forecasts on Dec. 12, 2025

Elevance Health, Inc. (NYSE: ELV) is drawing fresh investor attention on December 12, 2025 as credit-rating updates and U.S. policy headlines collide with a stock that has recently rebounded sharply. The latest developments arrive at a sensitive moment for managed-care names, with Wall Street weighing medical-cost trends, Medicaid rate dynamics, and the looming Affordable Care Act (ACA) subsidy deadline. As of Friday’s latest trade, ELV stock was around $360, after swinging between the day’s high and low in moderately active trading. What’s moving Elevance Health stock on Dec. 12, 2025 Key drivers investors are tracking today: ELV stock price check:
12 December 2025
·
Elevance Health (ELV) Stock News Today: ACA Subsidy Deadline Looms, Fitch Affirms A- Rating, and Analysts See Modest Upside (Dec. 12, 2025)

Elevance Health (ELV) Stock News Today: ACA Subsidy Deadline Looms, Fitch Affirms A- Rating, and Analysts See Modest Upside (Dec. 12, 2025)

Elevance Health (NYSE: ELV) is stabilizing near the $360 level after a sharp rebound, while Washington’s failure to extend ACA subsidies raises new 2026 uncertainty. Here’s the latest news, credit outlook, analyst forecasts, and technical setup as of December 12, 2025. Published: December 12, 2025 Elevance Health, Inc. (NYSE: ELV ) is ending the week with investors balancing two powerful forces: a meaningful technical rebound in the shares and a fresh policy shock from Washington that could reshape the Affordable Care Act (ACA) marketplace in 2026. As of late morning on Dec. 12, 2025 , Elevance was hovering around $360.52
12 December 2025
Elevance Health (ELV) Stock: December 2025 Outlook After Q3 Earnings Beat, Legal Headwinds and New Analyst Targets

Elevance Health (ELV) Stock: December 2025 Outlook After Q3 Earnings Beat, Legal Headwinds and New Analyst Targets

As of early December 3, 2025, Elevance Health, Inc. (NYSE: ELV) is trading around $331 per share, leaving the managed-care giant roughly 30% below its 52‑week high near $459, even after a strong third‑quarter earnings beat and renewed institutional buying.Investing.com+1 Over the past 12 months the stock is down about 18%, significantly lagging the S&P 500.PortfoliosLab This article pulls together the latest news, forecasts and analysis available as of December 2, 2025, to give a comprehensive view of where Elevance Health stock stands now and what markets are pricing in for 2026 and beyond. 1. Where Elevance Health Stock Stands
3 December 2025
·
1 2

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop